Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors
Louis M. Scott, … , Andrew D. Dick, Sofia Theodoropoulou
Louis M. Scott, … , Andrew D. Dick, Sofia Theodoropoulou
Published April 22, 2021
Citation Information: JCI Insight. 2021;6(8):e129429. https://doi.org/10.1172/jci.insight.129429.
View: Text | PDF
Research Article Metabolism Ophthalmology

Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors

  • Text
  • PDF
Abstract

It remains unresolved how retinal pigment epithelial cell metabolism is regulated following immune activation to maintain retinal homeostasis and retinal function. We exposed retinal pigment epithelium (RPE) to several stress signals, particularly Toll-like receptor stimulation, and uncovered an ability of RPE to adapt their metabolic preference on aerobic glycolysis or oxidative glucose metabolism in response to different immune stimuli. We have identified interleukin-33 (IL-33) as a key metabolic checkpoint that antagonizes the Warburg effect to ensure the functional stability of the RPE. The identification of IL-33 as a key regulator of mitochondrial metabolism suggests roles for the cytokine that go beyond its extracellular “alarmin” activities. IL-33 exerts control over mitochondrial respiration in RPE by facilitating oxidative pyruvate catabolism. We have also revealed that in the absence of IL-33, mitochondrial function declined and resultant bioenergetic switching was aligned with altered mitochondrial morphology. Our data not only shed new light on the molecular pathway of activation of mitochondrial respiration in RPE in response to immune stressors but also uncover a potentially novel role of nuclear intrinsic IL-33 as a metabolic checkpoint regulator.

Authors

Louis M. Scott, Emma E. Vincent, Natalie Hudson, Chris Neal, Nicholas Jones, Ed C. Lavelle, Matthew Campbell, Andrew P. Halestrap, Andrew D. Dick, Sofia Theodoropoulou

×

Figure 3

IL-33 increases bioenergetic demand.

Options: View larger image (or click on image) Download as PowerPoint
IL-33 increases bioenergetic demand.
(A) Mitochondrial stress test from ...
(A) Mitochondrial stress test from ARPE-19 treated with recombinant human IL-33 (rhIL-33) (100 ng/mL) 24 hours; XF injections were oligomycin (1 μM), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). (B) Glycolysis stress test from ARPE-19 treated with rhIL-33 (100 ng/mL) 24 hours; XF injections were glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (100 mM) (n = 3). (C) Labeled C13-glucose incorporation into ARPE-19 glycolytic metabolites treated 24 hours with rhIL-33 (100 ng/mL) (n = 3). (D) Labeled C13-glucose incorporation into ARPE-19 TCA metabolites treated as in C. (E) Mass isotopomer distribution of C13-glucose–derived carbon into fumarate (M+2), succinate (M+2), and citrate (M+2) metabolite pools (n = 3). (F) ARPE-19 treated 24 hours with rhIL-33 (100 ng/mL); glucose concentrations were measured in the media prior/following treatment and expressed as relative consumption (n = 3). (G) Modified mitochondrial stress test including a third injection of etomoxir (3 μg/mL) of ARPE-19 cells treated 24 hours with rhIL-33 (100 ng/mL) (n = 3). (H) Relative levels of malonyl CoA detected in whole cell lysates of ARPE-19 (n = 3). ARPE-19 treated 24 hours with rhIL-33 (100ng/mL); (I) RT-PCR relative gene expression or (J and K) protein was extracted and immunoblot analysis was used to determine the expression of PKM2, GLUT1, and PC (n = 3). (L) ARPE-19 were treated with rhIL-33 (100 ng/mL) 12 hours before treatment with H2O2 (1 mM) 24 hours; LDH release was quantified in supernatants and expressed as relative to untreated control (n = 4). (M) ARPE-19 were treated with rhIL-33 (100 ng/mL) 12 hours before treatment with H2O2 (1 mM) 24 hours; an MTT assay was used to determine cell viability and expressed as a percentage of untreated control (n = 4). (N) Modified mitochondrial stress test of ARPE-19 treated 24 hours with rhIL-33 (100 ng/mL); XF injections were H2O2 (1 mM), oligomycin (1 μM), FCCP (0.5 μM), and rotenone/antimycin A (1 μM) (n = 3). Data are expressed as means ± SD from at least 3 independent experiments. (A, B, and G) Represent the biological repeats from 3 independent experiments (n = 3); each biological repeat is the mean of 2 technical repeats (2 seahorse wells/experiment). (N) Represents the biological repeats from 3 independent experiments (n = 3); each biological repeat is the mean of 2 technical repeats or single technical repeat (1 or 2 seahorse wells/experiment). One-way ANOVA, Dunnett’s multiple comparisons test; *P < 0.05,**P < 0.01, ***P < 0.005.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts